Return on Invested Capital (ROIC): 11.40%
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of 11.40% is 28% below its 5-year average of 15.83%, near the low end of its 5-year range (10.74%–20.09%).
As of Sunday, June 28, 2026. 2.98% above its 12-month average of 11.07%.
EW Return on Invested Capital (ROIC) Chart
Annual fiscal-year return on invested capital; no daily interpolation.
EW Average Return on Invested Capital (ROIC) Chart
EW Current vs Average Return on Invested Capital (ROIC) Chart
EW Return on Invested Capital (ROIC) Metrics
RETURN ON INVESTED CAPITAL (ROIC)
11.40%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
11.07%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
14.43%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
15.83%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
16.15%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
15.68%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
14.93%
CURRENT VS TTM AVG
+2.98%
CURRENT VS 3Y AVG
-21.00%
CURRENT VS 5Y AVG
-27.97%
CURRENT VS 10Y AVG
-29.42%
CURRENT VS 15Y AVG
-27.28%
CURRENT VS 20Y AVG
-23.64%
EW Competitors' Return on Invested Capital (ROIC)
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Edwards Lifesciences Corporation (EW) | $52.27B | 11.40% | 11.07% | 14.43% | 15.83% |
| Cencora, Inc. (COR)vs › | $55.67B | 13.23% | 15.09% | 14.58% | 13.58% |
| Cardinal Health, Inc. (CAH)vs › | $55.72B | 11.37% | 10.09% | 4.86% | -0.22% |
| Becton, Dickinson and Company (BDX)vs › | $56.49B | 4.73% | 4.38% | 4.32% | 3.88% |
| Humana Inc. (HUM)vs › | $46.08B | 3.12% | 3.25% | 5.37% | 7.01% |
| IDEXX Laboratories, Inc. (IDXX)vs › | $43.50B | 40.27% | 37.07% | 34.89% | 35.94% |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $65.20B | 8.51% | 9.70% | 12.91% | 18.22% |
| Boston Scientific Corporation (BSX)vs › | $65.74B | 8.78% | 7.46% | 6.12% | 5.55% |
| Agilent Technologies, Inc. (A)vs › | $38.41B | 12.57% | 12.57% | 13.57% | 12.73% |
| Medline Inc. (MDLN)vs › | $32.87B | 5.69% | 6.03% | 3.95% | 3.95% |
Capital Efficiency
ROIC
11.4%
ROE
10.6%
Return on Invested Capital (ROIC) Formula & Definition
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Return on Invested Capital (ROIC) FAQ
- What is the return on invested capital (ROIC) for Edwards Lifesciences Corporation (EW)?
- The return on invested capital (ROIC) for EW stock is 11.40%.
- Is Edwards Lifesciences Corporation's return on invested capital (ROIC) high or low?
- The return on invested capital (ROIC) of 11.40% is 28% below its 5-year average of 15.83%, near the low end of its 5-year range (10.74%–20.09%).
- What is the TTM average return on invested capital (ROIC) for Edwards Lifesciences Corporation (EW)?
- The TTM average return on invested capital (ROIC) for EW stock is 11.07%.
- What is the 3Y average return on invested capital (ROIC) for Edwards Lifesciences Corporation (EW)?
- The 3Y average return on invested capital (ROIC) for EW stock is 14.43%.
- What is the 5Y average return on invested capital (ROIC) for Edwards Lifesciences Corporation (EW)?
- The 5Y average return on invested capital (ROIC) for EW stock is 15.83%.
- What is the 10Y average return on invested capital (ROIC) for Edwards Lifesciences Corporation (EW)?
- The 10Y average return on invested capital (ROIC) for EW stock is 16.15%.
- What is the 15Y average return on invested capital (ROIC) for Edwards Lifesciences Corporation (EW)?
- The 15Y average return on invested capital (ROIC) for EW stock is 15.68%.
- What is the 20Y average return on invested capital (ROIC) for Edwards Lifesciences Corporation (EW)?
- The 20Y average return on invested capital (ROIC) for EW stock is 14.93%.
EW Return on Invested Capital (ROIC) History
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | 11.40% |
| 2024-12-31 | 10.74% |
| 2023-12-31 | 15.49% |
| 2022-12-31 | 20.09% |
| 2021-12-31 | 18.97% |
| 2020-12-31 | 18.27% |
| 2019-12-31 | 19.16% |
| 2018-12-31 | 23.30% |
| 2017-12-31 | 11.64% |
| 2016-12-31 | 15.82% |
| 2015-12-31 | 12.78% |
| 2014-12-31 | 11.18% |
| 2013-12-31 | 13.83% |
| 2012-12-31 | 15.87% |
| 2011-12-31 | 16.69% |
| 2010-12-31 | 15.61% |
| 2009-12-31 | 13.23% |
| 2008-12-31 | 14.35% |
| 2007-12-31 | 11.42% |
| 2006-12-31 | 12.13% |
| 2005-12-31 | 11.53% |
| 2004-12-31 | 0.95% |
| 2003-12-31 | 12.61% |
| 2002-12-31 | 6.40% |
| 2001-12-31 | 3.04% |
| 2000-12-31 | 10.22% |
| 1999-12-31 | 6.63% |
Related Metrics
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Bernard J. Zovighian